IR Notice
Dear Investors, This is John Rim, CEO of Samsung Biologics. We sincerely appreciate your continued trust and support this year. 2021, our 10th year since the foundation of Samsung Biologics, has come to an end. Despite continued worldwide uncertainties, now greater than ever due to the prolonged COVID-19 pandemic, our three plants all maintained stable utilization thanks to our strong backlog and operational excellence. In addition, we are proud to highlight the following significant achievements:
- COVID-19 Vaccine/Drug CMO
- Moderna Vaccine DP Manufacturing Contract GSK/VIR, Lilly, AZ Antibody MFG Contracts
- Multi Modal Plant Expansion
- Songdo Section 5 (10,279m²) Land Acquisition
- mRNA DS Expansion
- May 21 Announced 1 Half 22 GMP-Ready Partnership with "Greenlight Biosciences
- S-CellerateTM Launch
- Accelerated platform for cell line development
We have also bolstered our efforts on ESG (Environmental, Social and Governance) management and accomplished the following:
- 5 Global ISO Certifications ISO 22301, ISO 45001, ISO 14001, ISO 50001, ISO 9001
- First Sustainability Report Issued
- Frontier-1.5D Participation
- ESG Rating 'A Grade' from KCGS
- Dow Jones Sustainability World Index Inclusion
- SMI Health Systems Supply Chains Working Group Champion *Sustainable Market Initiative
As everyone struggled together to return to normal, Samsung Biologics was proud to serve our part by not only providing high quality, end-to-end CDMO services crucial to our global clients, but also as a responsible member of society for greater sustainability. In 2022, we will continue to put forth our best efforts to pursue a better life for humanity in addition to our continuous growth. In our journey to a brighter future, we will continue to actively communicate with investors to update on our progress and results. This winter feels colder than ever with the pandemic, and we wish you an abundance of joy, health, and a happy year-end and New Year's holidays.
Thank you. Sincerely, John Rim President and CEO, Samsung Biologics
Dear Investors, This is John Rim, CEO of Samsung Biologics. We sincerely appreciate your continued trust and support this year. 2021, our 10th year since the foundation of Samsung Biologics, has come to an end. Despite continued worldwide uncertainties, now greater than ever due to the prolonged COVID-19 pandemic, our three plants all maintained stable utilization thanks to our strong backlog and operational excellence. In addition, we are proud to highlight the following significant achievements:
- COVID-19 Vaccine/Drug CMO
- Moderna Vaccine DP Manufacturing Contract GSK/VIR, Lilly, AZ Antibody MFG Contracts
- Multi Modal Plant Expansion
- Songdo Section 5 (10,279m²) Land Acquisition
- mRNA DS Expansion
- May 21 Announced 1 Half 22 GMP-Ready Partnership with "Greenlight Biosciences
- S-CellerateTM Launch
- Accelerated platform for cell line development
We have also bolstered our efforts on ESG (Environmental, Social and Governance) management and accomplished the following:
- 5 Global ISO Certifications ISO 22301, ISO 45001, ISO 14001, ISO 50001, ISO 9001
- First Sustainability Report Issued
- Frontier-1.5D Participation
- ESG Rating 'A Grade' from KCGS
- Dow Jones Sustainability World Index Inclusion
- SMI Health Systems Supply Chains Working Group Champion *Sustainable Market Initiative
As everyone struggled together to return to normal, Samsung Biologics was proud to serve our part by not only providing high quality, end-to-end CDMO services crucial to our global clients, but also as a responsible member of society for greater sustainability. In 2022, we will continue to put forth our best efforts to pursue a better life for humanity in addition to our continuous growth. In our journey to a brighter future, we will continue to actively communicate with investors to update on our progress and results. This winter feels colder than ever with the pandemic, and we wish you an abundance of joy, health, and a happy year-end and New Year's holidays.
Thank you. Sincerely, John Rim President and CEO, Samsung Biologics